Heart Failure Life Expectancy Calculator
Predict 1-year and 3-year survival odds using the MAGGIC score
Patient Information
Basic Demographics
Calculated BMI: 24.2 kg/m²
Laboratory Values
Normal: 0.7-1.3 mg/dL
Normal: 50-70%
Normal: <120 mmHg
Clinical Status
Medications and Medical History
Heart Failure Life Expectancy Results
Risk Interpretation
Patient has moderate risk requiring careful monitoring and optimization of heart failure therapy.
Example Patient Case
Patient: 68-year-old Male with Heart Failure
Demographics: 68 years old, male, BMI 26 kg/m²
Laboratory: Creatinine 1.4 mg/dL, EF 25%
Vital Signs: SBP 110 mmHg
Functional Status: NYHA Class III
Medications: Taking ACEi and beta-blocker
Comorbidities: COPD, diabetes
MAGGIC Score Calculation
Male: +1 point
Age 65-69 with EF <30%: +4 points
BMI 25-29: +2 points
Creatinine 110-129 µmol/L: +2 points
EF 25-29%: +5 points
SBP 110-119 with EF <30%: +4 points
NYHA Class III: +6 points
COPD: +2 points, Diabetes: +3 points
Total MAGGIC Score: 29 (High Risk)
NYHA Functional Classes
Class I
No symptoms with ordinary activity
Class II
Symptoms with ordinary activity
Class III
Symptoms with less than ordinary activity
Class IV
Symptoms at rest
Key Risk Factors
Low ejection fraction
Advanced age
High NYHA class
Kidney dysfunction
Low BMI
Low systolic blood pressure
General HF Survival Rates
General population averages. Individual results may vary based on specific risk factors.
Understanding the MAGGIC Risk Score
Purpose and Application
The MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) risk score is a validated tool for predicting 1-year and 3-year survival in patients with heart failure, developed from a meta-analysis of over 39,000 patients.
Clinical Validation
Developed by Pocock et al., this score has been extensively validated across diverse populations and is widely used in clinical practice and research for heart failure prognosis assessment.
Key Principles
Important Considerations:
- • Provides population-based estimates, not individual certainty
- • Should guide treatment intensity and planning
- • Must be interpreted with clinical judgment
- • Regular reassessment is important as condition changes
Important: This calculator provides statistical estimates based on population data and should never replace comprehensive clinical assessment or influence life-sustaining treatment decisions without careful consideration.
Treatment Optimization Strategies
Guideline-Directed Medical Therapy
Optimize ACE inhibitors, ARBs, beta-blockers, and aldosterone antagonists according to guidelines.
Device Therapy
Consider ICD, CRT, or LVAD for appropriate candidates with reduced ejection fraction.
Lifestyle Modifications
Sodium restriction, fluid management, exercise training, and smoking cessation.
Heart Failure Stages and Prognosis
ACC/AHA Stages
- Stage A: At risk but no structural heart disease
- Stage B: Structural heart disease but no symptoms
- Stage C: Structural heart disease with current/prior symptoms
- Stage D: Refractory heart failure requiring specialized interventions
Prognostic Factors
- • Left ventricular ejection fraction
- • Functional capacity (NYHA class)
- • Kidney function
- • Natriuretic peptide levels
- • Comorbidities (diabetes, COPD)
- • Response to optimal medical therapy
Related Heart Failure Calculators
Important Medical Disclaimer
This Heart Failure Life Expectancy Calculator is designed for educational purposes and clinical reference only. It should never replace comprehensive clinical assessment or professional medical judgment regarding heart failure management.
Healthcare professionals should:
- Use MAGGIC score as part of comprehensive heart failure evaluation
- Consider individual patient factors beyond the calculated score
- Follow current heart failure guidelines (AHA/ACC, ESC)
- Regularly reassess prognosis as patient condition changes
- Use results to guide treatment intensity and care planning
- Never use this tool alone for end-of-life decision making
This tool is based on the MAGGIC meta-analysis and should be used in conjunction with current evidence-based guidelines for heart failure management and prognosis assessment.